Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden - PubMed (original) (raw)
Affiliations
- PMID: 9816314
Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden
R Mouawad et al. Clin Cancer Res. 1996 Aug.
Abstract
The involvement of interleukin (IL-) 6 in malignant disease has been investigated in a variety of different malignancies. To evaluate whether serum IL-6 is a useful disease marker in metastatic malignant melanoma (MMM), we studied the time course of endogenous IL-6 secretion in 41 patients treated with cisplatinum, IL-2, and IFN-alpha. Furthermore, the relationship of endogenous IL-6 concentrations to the tumor burden and/or the clinical response was also evaluated. The baseline serum IL-6 levels were significantly higher in patients with MMM than in the control group (P = 0.002). When tumor burden was taken into consideration, we found that IL-6 levels were higher in patients with high tumor burden than in patients with low tumor burden. During treatment in the whole patient population, a higher serum IL-6 level was observed in nonresponding as compared to responding patients at days 7 (P = 0.0005), 21 (P = 0.002), and 35 (P = 0.009). The follow-up of serum IL-6 in patients with MMM according to the tumor burden and clinical response demonstrated that: (a) IL-6 levels were significantly higher at days 7 and 21 in patients with high tumor burden as compared to those with low tumor burden; and (b) IL-6 levels remain significantly higher in nonresponding patients as compared to responding patients regardless of the tumor burden. From these results, we can conclude that endogenous IL-6 may play a role in the failure of IL-2 therapy in such patients, since the very early IL-6 increase is correlated with the tumor mass and nonresponse to biochemotherapy. Therefore, it seems that the early detection of endogenous IL-6 may represent valuable information for monitoring the response to biochemotherapy in patients with MMM.
Similar articles
- An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients.
Mouawad R, Soubrane C, Rixe O, Khayat D, Spano JP. Mouawad R, et al. Melanoma Res. 2006 Aug;16(4):335-40. doi: 10.1097/01.cmr.0000205022.25397.86. Melanoma Res. 2006. PMID: 16845329 - Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study.
Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Mouawad R, et al. Cytokines Cell Mol Ther. 2002;7(4):151-6. doi: 10.1080/13684730210002328. Cytokines Cell Mol Ther. 2002. PMID: 14660055 - Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
Zhang GJ, Adachi I. Zhang GJ, et al. Anticancer Res. 1999 Mar-Apr;19(2B):1427-32. Anticancer Res. 1999. PMID: 10365118 - [Measurement of five cytokines in the serum of malignant lymphoma patients].
Zhu H, Wang Y, Han X. Zhu H, et al. Zhonghua Xue Ye Xue Za Zhi. 1998 Feb;19(2):85-8. Zhonghua Xue Ye Xue Za Zhi. 1998. PMID: 10921109 Chinese. - Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W. Hauschild A, et al. Br J Cancer. 2001 Apr 20;84(8):1036-42. doi: 10.1054/bjoc.2001.1731. Br J Cancer. 2001. PMID: 11308250 Free PMC article. Clinical Trial.
Cited by
- Melanoma biomarkers: Vox clamantis in deserto (Review).
Al-Shaer M, Gollapudi D, Papageorgio C. Al-Shaer M, et al. Oncol Lett. 2010 May;1(3):399-405. doi: 10.3892/ol_00000070. Epub 2010 May 1. Oncol Lett. 2010. PMID: 22966315 Free PMC article. - Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.
von Felbert V, Córdoba F, Weissenberger J, Vallan C, Kato M, Nakashima I, Braathen LR, Weis J. von Felbert V, et al. Am J Pathol. 2005 Mar;166(3):831-41. doi: 10.1016/S0002-9440(10)62304-8. Am J Pathol. 2005. PMID: 15743795 Free PMC article. - Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker.
Wang Y, Ramachandran V, Sui D, Xu K, Haydu LE, Fang S, McQuade JL, Fisher SB, Lucci A, Keung EZ, Wargo J, Gershenwald JE, Ross MI, Lee JE. Wang Y, et al. J Invest Dermatol. 2022 Jul;142(7):2046-2049.e3. doi: 10.1016/j.jid.2021.12.012. Epub 2021 Dec 21. J Invest Dermatol. 2022. PMID: 34952092 Free PMC article. No abstract available. - The role of chronic inflammation in obesity-associated cancers.
Ramos-Nino ME. Ramos-Nino ME. ISRN Oncol. 2013 May 30;2013:697521. doi: 10.1155/2013/697521. Print 2013. ISRN Oncol. 2013. PMID: 23819063 Free PMC article. - Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer.
Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, Motohashi S, Yokoi S, Hiroshima K, Tagawa M, Nakayama T, Fujisawa T. Yamaji H, et al. Cancer Immunol Immunother. 2004 Sep;53(9):786-92. doi: 10.1007/s00262-004-0533-9. Epub 2004 Jun 4. Cancer Immunol Immunother. 2004. PMID: 15185009 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical